A carregar...
CYP2D6 haplotypes with enhancer SNP rs5758550 and rs16947 (*2 allele): implications for CYP2D6 genotyping panels
CYP2D6 metabolizes ~25% of all clinically used drugs, with numerous genetic polymorphisms affecting enzyme activity and drug response. Clinical utility of current CYP2D6 genotyping is partially compromised the unresolved complex haplotype structure of the CYP2D6 locus. We have identified a distal en...
Na minha lista:
| Publicado no: | Pharmacogenet Genomics |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6441960/ https://ncbi.nlm.nih.gov/pubmed/30520769 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FPC.0000000000000363 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|